MORGAN STANLEY PLC/CALL/ELI LILLY & CO/450/0.01/20.12.24 | Market Closed - Börse Stuttgart 11:57:12 28/06/2024 pm IST | ||
| 4.47 EUR | +1.82% |
|
| Current month | +24.86% | ||
| 1 month | +27.71% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 28/24/28 | 4.47 | +1.82% |
| 27/24/27 | 4.39 | -0.45% |
| 26/24/26 | 4.41 | +0.46% |
| 25/24/25 | 4.39 | +1.62% |
| 24/24/24 | 4.32 | +2.37% |
Delayed Quote Börse Stuttgart
Last update June 28, 2024 at 11:57 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | Morgan Stanley |
| WKN | MB5BYC |
| ISIN | DE000MB5BYC5 |
| Date issued | 05/04/2023 |
| Strike | 450 $ |
| Maturity | 20/12/2024 (174 Days) |
| Parity | 100 : 1 |
| Emission price | 0.31 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.47 € |
|---|---|
| Lowest since issue | 0.29 € |
| Spread | 0.01 € |
| Spread % | 0.23% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
905.4
USD
Average target price
868.9
USD
Spread / Average Target
-4.03%
- Stock Market
- Warrants
- Warrant
